Corcept Therapeutics Stock Forecast

Stock Price Forecast

The 5 analysts that cover Corcept Therapeutics stock have a consensus rating of "Buy" and an average price target of $107.2, which forecasts a 178.22% increase in the stock price over the next year. The lowest target is $60 and the highest is $150.

Price Target: $107.2 (+178.22%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$60	$107.2	$110	$150
Change	+55.72%	+178.22%	+185.49%	+289.31%

Analyst Ratings

The average analyst rating for Corcept Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	3	3	3	3	3	3
Buy	1	1	1	1	1	1
Hold	0	1	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Edward Nash Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $100 → $110	Strong Buy	Maintains	$100 → $110	+185.49%	Mar 26, 2026
Kalpit Patel Wolfe Research	Wolfe Research	Sell → Hold Upgrades n/a	Sell → Hold	Upgrades	n/a	n/a	Mar 26, 2026
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $67 → $60	Strong Buy	Maintains	$67 → $60	+55.72%	Mar 25, 2026
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $67 → $60	Strong Buy	Maintains	$67 → $60	+55.72%	Feb 25, 2026
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $105 → $67	Strong Buy	Maintains	$105 → $67	+73.89%	Feb 20, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

960.00M

from 761.41M

26.08%

from 761.41M

Revenue Next Year

1.26B

from 960.00M

31.04%

from 960.00M

EPS This Year

0.83

from 0.82

0.76%

from 0.82

EPS Next Year

2.24

from 0.83

171.11%

from 0.83

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	365.98M	401.86M	482.38M	675.04M	761.41M	960.00M	1.26B
Revenue Growth	3.42%	9.80%	20.04%	39.94%	12.79%	26.08%	31.04%
EPS	0.89	0.87	0.94	1.23	0.82	0.83	2.24
EPS Growth	4.71%	-2.25%	8.05%	30.85%	-33.33%	0.76%	171.11%
Forward PE	-	-	-	-	-	46.64	17.20
No. Analysts	-	-	-	-	-	8	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	1.1B	1.6B
Avg	960.0M	1.3B
Low	886.9M	949.5M

Revenue Growth

Revenue Growth	2026	2027
High	38.4%	67.8%
Avg	26.1%	31.0%
Low	16.5%	-1.1%

EPS Forecast

EPS	2026	2027
High	1.50	4.20
Avg	0.83	2.24
Low	0.27	0.35

EPS Growth

EPS Growth	2026	2027
High	83.1%	408.4%
Avg	0.8%	171.1%
Low	-66.5%	-57.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.